Tower Research Capital LLC (Trc) Revance Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,892 shares of RVNC stock, worth $17,712. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,892

Previous 21,980 68.64%

Holding current value

$17,712

Previous $56,000 69.64%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $38,776 - $38,776	-15,088 Reduced 68.64%	6,892 $17,000
Q2 2024 Aug 13, 2024	BUY	$2.34 - $4.73 $49,781 - $100,626	21,274 Added 3013.31%	21,980 $56,000
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $28,444 - $56,949	-6,117 Reduced 89.65%	706 $3,000
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $34,186 - $65,900	5,884 Added 626.62%	6,823 $59,000
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $26,770 - $58,513	-2,334 Reduced 71.31%	939 $10,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $22,254 - $33,886	901 Added 37.98%	3,273 $82,000
Q1 2023 May 09, 2023	SELL	$18.36 - $35.27 $13,053 - $25,076	-711 Reduced 23.06%	2,372 $76,000
Q4 2022 Feb 10, 2023	SELL	$18.32 - $30.66 $39,039 - $65,336	-2,131 Reduced 40.87%	3,083 $57,000
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $26,238 - $52,128	1,831 Added 54.12%	5,214 $141,000
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $27,912 - $49,429	2,423 Added 252.4%	3,383 $47,000
Q1 2022 May 12, 2022	SELL	$12.36 - $20.31 $6,044 - $9,931	-489 Reduced 33.75%	960 $19,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $12,298 - $27,507	-987 Reduced 40.52%	1,449 $24,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $223,538 - $287,963	-8,671 Reduced 78.07%	2,436 $68,000
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $118,724 - $141,051	4,430 Added 66.35%	11,107 $329,000
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $51,328 - $64,015	2,136 Added 47.04%	6,677 $187,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $196,995 - $238,481	-8,415 Reduced 64.95%	4,541 $129,000
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $149,415 - $220,617	6,432 Added 98.59%	12,956 $326,000
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $82,202 - $173,212	6,524 New	6,524 $159,000
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $37,006 - $82,595	-2,970 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$11.66 - $20.15 $20,638 - $35,665	1,770 Added 147.5%	2,970 $48,000
Q3 2019 Nov 05, 2019	BUY	$10.22 - $14.5 $12,264 - $17,400	1,200 New	1,200 $16,000
Q3 2018 Nov 13, 2018	SELL	$23.55 - $30.1 $5,793 - $7,404	-246 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$27.45 - $33.35 $6,752 - $8,204	246 New	246 $7,000
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $1,340 - $1,720	-46 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$24.55 - $36.3 $76,203 - $112,675	-3,104 Reduced 98.54%	46 $2,000
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $71,032 - $88,515	3,150	3,150 $87,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Revance Therapeutics, Inc. Transaction History